Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral Olorofim with Fluconazole or Posaconazole in AML
NCT03036046Phase 2Withdrawn
- Sponsor
- F2G
- Start
- Mar 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olorofim in invasive aspergillosis (IA), sponsored by F2G. Planned start Mar 2017; status: withdrawn.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03036046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036046.